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httpcense.Abstract Background: Published reference equations predicting Estimated-Lung-Age (ELA) did
not reliably predict Chronological-Lung-Age (CLA) data in North African population.
Aims: To develop and to validate novel reference equations for ELA from varied anthropomet-
ric data and FEV1.
Methods: Applying multiple regression analysis, equations predicting ELA were invented using
data from 540 never-smokers with normal spirometry (group I). Validation was made based on data
from 41 never-smokers with normal spirometry (group II). Equations were further applied for 91
subjects with conﬁrmed COPD.; BSA, Body-Surface-Area; CLA, Chronological-Lung-Age; COPD, Chronic Obstructive Pulmonary
A, Estimated-Lung-Age; FEFx, Forced Expiratory Flow when x% of FVC has been exhaled; FEV1, ﬁrst
C, Forced Vital Capacity; LA, Lung-Age; LOA, Limits-Of-Agreement; LLN, Lower-Limit-of-Normal;
w; n, number; OSA, Obstructive Sleep Apnea; PEF, Peak Expiratory Flow; RSD, Residual Standard
N, Upper-Limit-Of-Normal; r, coefﬁcient of correlation; r2, coefﬁcient of determination; 95% CI, 95%
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492 H. Ben Saad et al.Results: Novel regression equations allowing prediction of reference value of ELA and normal
limits of difference between ELA and CLA were elaborated in both sexes. In males, ELA (yrs) =
42.85  20.74 · FEV1 (L) + 47.41 · Body Surface Area (m2)  0.62 · Body-Mass-Index (BMI, kg/
m2). In females, ELA (yrs) = 64.64  8.00 · FEV1 (L)  0.17 · BMI (kg/m2) + 8.82 ·Height (m).
Normal limits of difference between ELA and CLA were ±16.9 yrs in males and ±14.8 yrs in
females. Established equations predicted ELA of group II with no signiﬁcant difference between
CLA and ELA in either sex (respectively, 42.9 ± 16.6 vs. 40.3 ± 13.7 yrs in males, 42.0 ± 13.5
vs. 45.6 ± 7.7 yrs in females) ELA was signiﬁcantly older than CLA age only in COPD with grades
III and IV ((ELA minus CLA) (yrs) averaged, respectively, +21.7, +26.4).
Conclusion: North African reference equations enrich the World Bank of reference equations
from which the physician should choose according to the patient’s ethnic background.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.Introduction
The single most useful intervention to improve lung function
in smokers, with or without, Chronic Obstructive Pulmonary
Disease (COPD) is smoking cessation [1,2]. One way to in-
crease the quit rate in smokers could be to communicate lung
function results in a manner that is easily understood and stim-
ulates the desire to quit [1].
To conquer the difﬁculty existing in the raw results of spi-
rometric measurements, the concept of Estimated-Lung-Age
(ELA) has been proposed [3]. ELA is an estimate that uses
the observed spirometric variable (often FEV1 for ﬁrst second
Forced Expiratory Volume) of a smoker to calculate the
approximate age of a healthy non-smoker with the same
spirometric variable based on reference values [3]. Its basis of
interpretation relies upon comparison of the Chronological-
Lung-Age (CLA) values with ELA predicted from available
reference equations [3–6]. Morris and Temple [3] proposed
the concept of ELA about 28 years ago, for USA population
using earlier American spirometry reference equations [7].
Four models of ELA reference equations were developed
and the most relevant model to determine ELA values was
the one using FEV1 [3].
To extend the clinical application of Lung-Age (LA), three
other reference equations predicting ELA have been recently
published [4–6]. In 2010, two reference equations were devel-
oped by Newbury et al. and by Hansen et al. for, respectively,
South Australian and USA populations [4,5]. In 2012, Yamag-
uchi et al. [6] have developed novel regression equations for
Japanese population. Hansen et al. [5] proposed a simpliﬁed
equation allowing LA estimation from the ratio between
FEV1 and Forced Vital Capacity (FVC). Newbury et al. [4] ap-
plied the same methods described by Morris and Temple [3]
with the equations being solved for age. Yamaguchi et al. [6]
have presented equations including various spirometric param-
eters such as FVC, FEV1, FEV1/FVC ratio, Peak Expiratory
Flow (PEF), Forced Expiratory Flow when x% of FVC has
been exhaled (FEFx, FEF50 and FEF25) and Maximal Mid-
Expiratory Flow (MMEF). Only two authors [3,6] have pro-
posed algorithms for judging the abnormality from spirometry
ELAwith presentation of a recommended sequence to interpret
ELA [3] or a recommendation to use the Upper-Limit-of-Nor-
mal and Lower-Limit-of-Normal (ULN, LLN, respectively)
[6], as recommended for spirometry [8]. These four published
studies [3–6] presented several limitations, previously described[9]: low sample size [4], sample may not be representative of a
normal population [3,4], skewed age distribution [3], use of
old spirometric data or equipment [3,5], application of old spi-
rometric methods [4], mathematical and statistical ﬂaws [3–5],
wide variation in ELA [4]. These methodological shortcomings
explain some discrepancies in the ﬁndings [9]. In North African
population, it was strongly suggested that existing LA equa-
tions [3–6] are in need of review [9]: these reference equations
did not reliably predict CLA data in a large group of Tunisian
healthy adults. In addition, among the four published equa-
tions [3–6], it was recommended to use, those developed for
healthy Japanese subjects aged 25–87 years [6]. The recommen-
dation was justiﬁed by several reasons [9].
How to evaluate ‘‘spirometric’’ ELA and what method is
approvable? This question was asked in 2011 [10], in order
to promote the development of ethnic-speciﬁc ELA regression
equations in various races. The need for normal values speciﬁc
to North African populations has been demonstrated for sev-
eral physiological parameters [9,11–18]. So, the applicability
and the reliability of published ELA reference equations [3–
6] should be assessed with regard to North African adult’s
population, in order to avoid erroneous clinical interpretation
of ELA data in this population.
Based on these backgrounds, the aims of the present study
are
(i) To establish novel regression equations allowing predic-
tion of the reference value of ELA and its normal limits
using the data harvested from a large number of healthy
Tunisian never-smokers with normal spirometric mea-
surements; and to propose an algorithm for judging
the abnormality of the ELA.
(ii) To validate the developed equations using the data
obtained from a second group of healthy never-smokers
with normal spirometry and two groups of subjects with
deteriorating pulmonary function; and
(iii) To compare the novel North African ELA reference
equations with those of Yamaguchi et al. [6].Population and methods
Study design
A large part of the design and methods was previously de-
scribed [9].
Lung age of North African adults 493The present cross-sectional study was performed over
16 month’s period in two Functional Exploration Laboratories
at the Occupational Medicine Group and at the Farhat HA-
CHED Hospital of Sousse, Tunisia.
The study was conducted in accordance with the Declara-
tion of Helsinki. Approval for the study was obtained from
the Hospital Ethics Committee, and written informed consent
was obtained from all study participants.
Subjects
Four groups were recruited: group I (equation group), group II
(validation group), groups III and IV (patients’ validation
groups).
Group I (equation group): healthy never-smokers with normal
spirometric measurements
Information about target population, previously detailed [9], is
presented in Appendix A. Subjects who declared, in the ques-
tionnaire, that they never smoked (cigarettes and/or narghile)
or having no more than incidental smoking experience before
the visit examination were selected and deﬁned as ‘‘never-
smokers’’. Criteria to deﬁne a healthy and ‘‘normal’’ person,
previously detailed [9], are presented in Appendix A. ‘‘Healthy
never-smokers’’ in whom spirometric measurements were with-
in normal ranges were deﬁned as ‘‘healthy never-smokers with
normal spirometric measurements’’. The spirometric normality
was judged by consulting the following criteria: FEV1, FVC
and FEV1/FVC > LLN of each parameter [8]. Thus, the total
of 540 participants (176 males) with age distribution ranging
between 19 and 90 years-old, who visited the two laboratories
from February 2011 to January 2012, met the criteria of
‘‘healthy never-smokers with normal spirometric measure-
ments’’. These participants were categorized as group I. Their
diverse parameters were used for constructing the novel predic-
tion equations of ELA in both sexes.
Group II (healthy subject’s validation group): healthy never-
smokers with normal spirometric measurements
Similarly, 41 participants (20 males) with age distribution
ranging between 22 and 89 years-old, who visited the two
laboratories from February 2012 to April 2012, satisﬁed the
criteria of ‘‘healthy never-smokers with normal spirometric mea-
surements’’ and were assigned to group II. Members of group
II, who did not overlap those of group I, were devoted to
validation of the novel prediction equations of ELA in both
sexes.
Group III (patients’ validation group): COPD patients
Ninety one smoker subjects (65 males) with age ranging from
19 to 80 years-old, visiting the Functional Exploration Labo-
ratory at the Farhat HACHED Hospital from February
2012 to April 2012, showing an after bronchodilator FEV1/
FVC less than 0.70, satisﬁed the criteria of COPD [19].
Group IV (patient’s validation group): obstructive sleep apnea
patients
Sixty severe OSA patients (42 males; apnea hypopnea in-
dex > 30/h) with age ranging from 26 to 70 years-old, were ad-
dressed to the Functional Exploration Laboratory at theFarhat HACHED Hospital from February 2012 to April
2012, for spirometry and 6-min walk test [20].
Data of participants allocated to groups III and IV were
used for certifying whether the newly developed equations
would reliably detect the abnormal ELA in subjects with
COPD or severe OSA.
Collected data
Dependent variable: CLA.
Independent variables: sex (male, female), anthropometric
data (age, weight, height, Body Mass Index (BMI), Body Sur-
face Area (BSA)), parity, spirometric data (FVC, FEV1, PEF,
MMEF, FEFx, FEV1/FVC ratio).
Data collection procedure
Medical questionnaire and tobacco use evaluation
Data were collected using a medical questionnaire [21]. It was
used to assess subject characteristics (cigarettes and narghile
use [22–24], medical, surgical, and gynecologic–obstetric histo-
ries and medication use).
Measurement technique and applied deﬁnition
Anthropometric measurements and parity: the decimal age
(accuracy to 0.1 years) was calculated from the date of mea-
surement and the date of birth [25]. Standing height and weight
were measured using a stadiometer and expressed to the near-
est centimeter and kilogram, respectively. Depending on calcu-
lated BMI (kg/m2), six obesity statuses, described in Appendix
A, were deﬁned [26]: underweight, normal weight, overweight
and moderate or severe or massive obesity. BSA was calcu-
lated [27]. Parity referred to the number of offspring.
Spirometry measurements: spirometry, performed accord-
ing to the international recommendations [28], was previously
described [9]. A standard uni-directional digital volume trans-
ducer equipment (Micro Medical Limited. PO Box 6, Roches-
ter. Kent ME1 2AZ England) was used. The spirometric data
[FVC (L); FEV1 (L); FEFx (L/s), PEF (L/s), FEV1/FVC ratio
(absolute value)] were measured/calculated. Additional infor-
mation about spirometry measurements is included in Appen-
dix A. The reversibility test, done according international
recommendations [8,29,30], was applied only to group III
(COPD patients). The international classiﬁcation of severity
of airﬂow obstruction in COPD, based on post-bronchodilator
FEV1, was applied [19]: grade I (mild): FEV1 > 80%; grade II
(moderate): 50% 6 FEV1 < 80%; grade III (severe):
30% 6 FEV1 < 50%; grade IV (very severe): FEV1 < 30%.
Statistical analysis
Expression modes of results
The Kolmogorov–Smirnov test was used to analyze distribu-
tion of variables [31]. When the distribution was normal and
the variances were equal, the results were expressed by their
mean ± Standard-Deviation (SD) and 95% conﬁdence-inter-
val (95% CI). If the distribution was not normal, the results
were expressed by their median (1st–3rd quartiles). The chi-2
test was used to compare percentages. Preliminary descriptive
analysis included frequencies for categorical variables and
mean ± SD or median (1st–3rd quartiles) for continuous ones.
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of ELA)
The dependent variable (CLA) was normally distributed. T-
tests were used to evaluate the associations between CLA
and categorical variables (sex) and the Pearson product-mo-
ment correlation coefﬁcients (r) and determination coefﬁcient
(r2) evaluated the associations between CLA and continuous
measures [height, weight, BMI, BSA, spirometric data ex-
pressed in absolute values]. The linearity of the association be-
tween the CLA and the continuous measures was checked
graphically (scatterplots) by plotting each regressor against
CLA. Only signiﬁcantly and linearly associated variables were
entered into the model. A linear regression model was used to
evaluate the independent variables explaining the variance in
CLA. Candidate variables were stepped into the model with
a stepwise selection method. To determine entry and removal
from the model, signiﬁcance levels of 0.15 and 0.05 were used,
respectively. No colinearity between predictors was detected
with variance inﬂation factors.
The method was well exposed by Yamaguchi et al. [6]. The
implicit assumption in the original method of Morris and Tem-
ple [3] is that LA is expressed by a linear function of FEV1 and
height, the latter of which works as the factor supplementing
the inﬂuence of anthropometric difference on FEV1. However,
other data (such as sex, weight, BSA, BMI, parity) and spiro-
metric parameters may provide useful information on ELA, as
well. We, therefore, hypothesized that CLA (dependent vari-
able) would be predicted from a function including anthropo-
metric data (sex (0. Male; 1. Female), height (m), weight (kg),
BMI (kg/m2), BSA (m2), parity (numerical)) for females and
various spirometric parameters as independent variables and
deﬁned it as ELA (Box 1).Box 1Eq. (1)
ELA (yrs) = a0 + a1 · Sex + a2 ·Height + a3 ·Weight
+ a4 · BMI + a5 · BSA + a6 · FVC + a7 · FEV1 + a8
· FEV1/FVC ratio + a9 · PEF + a10 ·MMEF+ a11 ·
FEF25 + a12 · FEF50 + a13 · FEF75 + a14 · Parity (if
women).In Eq. (1), ai (i= 1–14) is the partial regression coefﬁcient
for a particular explanatory variable, while a0 is the invariable
constant.
ELA simpliﬁed reference equations
Due to the inadequacy of the published ELA equations [9] and
for practical reasons and daily interpretation especially in pa-
tient screening, a reference equation should include only data
which can be easily measured/calculated and are signiﬁcantly
associated with ELA. Therefore, we established another step-
wise linear regression model using FEV1 and previously signif-
icant anthropometric data shown to be predictors of ELA
(Box 2).Box 2Eq. (2)
ELA (yrs) = a0 + a1 · Sex + a2 ·Height + a3 ·
Weight + a4 · BMI + a5 · BSA+ a6 · FEV1In Eq. (2), ai (i= 1–6) is the partial regression coefﬁcient
for a particular explanatory variable, while a0 is the invariable
constant.The normal limits, i.e., ULN and LLN for the disparity be-
tween ELA and CLA, deﬁned as deltaLA (CLA minus ELA),
were evaluated with the standardized residual called Z-score
[31]. The ULN and LLN were assumed to be equal to 95th
and 5th percentiles of Z distribution, corresponding to Z-scores
of ±1.64, respectively [95% CI = 1.64 · Residual SD (RSD)).
Validation of prediction equations
Since the concept of ELA is lacking in the physiological basis,
Eq. (2) should be taken as the empirical one and needs valida-
tion concerning its applicability to ELA prediction. Therefore,
ELAs of groups I and II subjects (normal spirometric measure-
ments) and that of groups III and IV subjects (patients groups’)
were calculated by applying the regression equations con-
structed on the ground of Eq. (2). CLAs were compared with
ELAs calculated from the local retained reference equation
(Eq. (2)) in many ways:
(i) A non parametric test (Wilcoxon matched pairs test)
was used to compare ELA vs. CLA for males, females
and the total sample of groups I-IV
(ii) As proposed by Bland and Altman [32], comparisons
between CLA and ELA, of groups I and II, were per-
formed by means of the Limits-Of-Agreement (LOA),
where deltaLA were plotted against the corresponding
mean value. From these data, LOA were then calculated
(mean deltaLA ± 1.96 SD).
(iii) CLA values of group II were compared with ELA using
scatterplots and paired T-tests,
(iv) The numbers (relative frequencies) of subjects of groups
II–IV, in whom the ELA exceeded its ULN were
determined.
(v) The difference between the four COPD grades was
judged in terms of the one-way ANOVA followed by
the multiple comparison of the Tukey test.
Comparison with the ELA from the Japanese reference
equations
Yamaguchi et al. [6] have developed two reference equation
models presented in Appendix A (Box A.1) for the Japanese
population aged 25–87 years. CLAs of the group II were com-
pared with ELAs calculated from the Japanese reference equa-
tions [6] in two ways:
(i) CLA values, for males and females, were compared with
ELA using scatterplots and paired T-tests,
(ii) Determination of the number of subjects in whom the
ELA exceeded its ULN.
Analyses were carried out using Statistica software (Statis-
tica Kernel version 6; StatSoft, Paris, France). Signiﬁcance was
set at the 0.05 level.
Results
Descriptive data
Group I (equation group)
An initial sample of 669 volunteer adults was examined. Non-
inclusion criteria, previously detailed [9], were found in 129
Lung age of North African adults 495subjects. The dependent variable (CLA) was normally distrib-
uted (Kolmogorov–Smirnov = 0.07, p< 0.05). The age and
sex distribution of the 540 healthy subjects (176 males) was
previously described [9]. Table 1 exposes the anthropometric
and spirometric data of the included 540 healthy never-smok-
ers with normal spirometric measurements. The main conclu-
sions are: (i) female subgroup is signiﬁcantly older and
shorter than the male subgroup and contains a signiﬁcantly
lower percentage of subjects with a normal weight; (ii) spirom-
etry data of the females’ subgroup are signiﬁcantly higher than
those of the males’ subgroup (except for FEV1/FVC).
Group II (healthy subject’s validation group)
Table 1 exposes the anthropometric and spirometric data of
the included 41 healthy never-smokers with normal spiromet-
ric measurements. The main remark is that spirometry data
(expressed as% reference) of the females’ subgroup are signif-
icantly higher than those of the males’ subgroup (except for
FEV1/FVC and FEF25).
Groups III and IV (patients’ validation groups)
Table 2 exposes the anthropometric and spirometric data of
the 91 COPD (group III) and the 60 severe OSA patients
(group IV). Compared to the total sample group I, the total
sample group III is signiﬁcantly older and thin and has aTable 1 Anthropometric and spirometric data of groups I and II:
Group I: equation group
Male Female
(n= 176) (n= 364)
Chronological-Lung-Age (Yr) 45.4 ± 15.5 50.5 ± 11.4a
Estimated-Lung-Age (Yr) 45.4 ± 11.6 50.5 ± 7.1a
Height (m) 1.66 ± 0.08 1.63 ± 0.11a
Weight (kg) 74 ± 12 73 ± 12
Body-Mass-Index (kg/m2) 26.8 ± 3.8 27.5 ± 3.5a
Body-Surface-Area (m2) 1.81 ± 0.17 1.79 ± 0.19
Parity (numerical) 5 ± 3
FEV1 (L) 3.22 ± 0.62 2.97 ± 1.00
a
FEV1 (%) 97 ± 11 114 ± 21
a
FVC (L) 3.81 ± 0.72 3.51 ± 1.19a
FVC (%) 95 ± 11 114 ± 22a
FEV1/FVC (absolute value) 0.85 ± 0.06 0.85 ± 0.06
PEF (L/s) 7.32 ± 1.58 6.45 ± 2.23a
PEF (%) 88 ± 19 100 ± 27a
FEF25 (L/s) 1.99 ± 0.74 1.93 ± 1.16
FEF25 (%) 111 ± 36 123 ± 71
a
FEF50 (L/s) 4.69 ± 1.37 4.28 ± 1.54
a
FEF50 (%) 103 ± 27 108 ± 30
FEF75 (L/s) 6.68 ± 1.55 5.80 ± 2.42
a
FEF75 (%) 92 ± 20 102 ± 37
a
MMEF (L/s) 4.04 ± 1.13 3.75 ± 1.60a
MMEF (%) 102 ± 24 113 ± 40a
Obesity status
Normal weight 58 (33) 88 (24)b
Overweight 81 (46) 178 (49)
Moderate obesity 37 (21) 98 (27)
For abbreviations, see abbreviation list. Data are mean ± SD except for
a p< 0.05 (Student-test for the same group): male vs. female.
b p< 0.05 (Chi-2 for the same group): male vs. female.
c p< 0.05 (Student-test for group I vs. group II): (male vs. male), (fem
d p< 0.05 (Chi-2): male group I vs. male group II, female group I vs. f
e p< 0.05 (non parametric-test for each group): ELA vs. CLA for malsigniﬁcantly lower spirometric data. Compared to the total
sample group I, the total sample group IV is signiﬁcantly hea-
vier and has a signiﬁcantly lower spirometric data.
Analytical data
Univariate analysis
CLA was different between males and females (Table 1). Coef-
ﬁcient correlation (r) between the CLA and the quantitative
subject’s data is shown in Table A.1 (Appendix A). In brief,
in males of group I, CLA was signiﬁcantly correlated with all
the studied parameters except of height, PEF and FEF75. In fe-
males and total sample of group I, CLA was signiﬁcantly corre-
lated with all the studied parameters except FEV1/FVC ratio.
Multiple regression analysis (ELA inﬂuencing factors)
Data about multiple regression analysis are shown in Table 3.
In the females, three anthropometric data (parity, height and
BMI) and ﬁve spirometric parameters (FEV1, PEF, MMEF,
FVC, and FEF25) were picked up as signiﬁcant inﬂuencing fac-
tors of ELA. In the males, two anthropometric data (BSA and
BMI) and ﬁve spirometric parameters (FEF25, FVC, FEV1,
FEF50, and MMEF) were statistically selected as inﬂuencing
factors of ELA. In the total sample, ﬁve anthropometric data
(height, sex, BSA, weight and BMI) and ﬁve spirometrichealthy never-smokers with normal spirometric measurements.
Group II: validation group
Total sample Male Female Total sample
(n= 540) (n= 20) (n= 21) (n= 41)
48.8 ± 13.1 42.9 ± 16.6 42.0 ± 13.5c 42.5 ± 14.9c
48.8 ± 9.1 40.3 ± 13.7 45.6 ± 7.7c 43.0 ± 11.2c
1.64 ± 0.10 1.65 ± 0.10 1.65 ± 0.12 1.65 ± 0.11
73 ± 12 70 ± 9 70 ± 12 70 ± 10
27.3 ± 3.6 25.8 ± 3.3 25.7 ± 3.7c 25.8 ± 3.5c
1.79 ± 018 1.78 ± 0.16 1.76 ± 0.20 1.77 ± 0.18
3 ± 2
3.05 ± 0.90 3.42 ± 0.72 3.64 ± 1.08c 3.53 ± 0.92c
109 ± 20 102 ± 16 127 ± 21a,c 115 ± 22
3.61 ± 1.07 4.01 ± 0.84 4.25 ± 1.32c 4.13 ± 1.10c
108 ± 21 99 ± 13 127 ± 25a,c 113 ± 25
0.85 ± 0.06 0.85 ± 0.06 0.86 ± 0.07 0.86 ± 0.06
6.73 ± 2.08 7.10 ± 2.08 7.35 ± 2.33 7.23 ± 2.19
96 ± 25 84 ± 22 108 ± 27a 96 ± 27
1.95 ± 1.04 2.04 ± 0.62 2.20 ± 0.79 2.12 ± 0.70
119 ± 62 124 ± 79 122 ± 34 123 ± 59
4.41 ± 1.50 4.64 ± 1.03 5.15 ± 1.77c 4.90 ± 1.46c
107 ± 29 103 ± 26 122 ± 34a,c 113 ± 32
6.09 ± 2.21 6.43 ± 2.01 6.95 ± 2.31c 6.70 ± 2.16
99 ± 33 88 ± 25 116 ± 32a 103 ± 32
3.84 ± 1.47 3.98 ± 0.76 4.70 ± 1.78c 4.35 ± 1.41c
110 ± 36 101 ± 28 129 ± 38a 115 ± 36
146 (27) 6 (30) 8 (38) 14 (34)
259 (48) 11 (55) 9 (43) 20 (49)
135 (25) 3 (15) 4 (19) 7 (17)
obesity status (data are number (percentage)).
ale vs. female) and (total sample vs. total sample).
emale group II.
e, female and the total sample.
496 H. Ben Saad et al.parameters (FEV1, PEF, MMEF, FVC and FEF25) were sta-
tistically selected as inﬂuencing factors of ELA. Thus, the inde-
pendent variables included in the linear stepwise multiple
regression models are presented in Table 3. The linear stepwise
multiple regression equation for the total sample is shown by
Eq. (3) (Box 3).Box 3Eq. (3)
ELA (yrs) = 210.67  5.48 · FEV1 (L) + 2.17 · PEF
(L/s)  265.41 · Height (m) + 3.84 · Sex (0. Male; 1.
Female)  2.97 ·MMEF (L/s)  3.99 · FVC (L) 
0.857 · FEF25 (L/s) + 289.51 · BSA (m2)  1.94 · BMI
(kg/m2)The cumulative r2 were 0.45, 0.62 and 0.47, respectively for fe-
males, males and the total sample. The 95% CI (in years) were
14.04, 15.91 and 15.70, respectively for females, males and the
total sample.
ELA simpliﬁed reference equations
The simpliﬁed reference equations are exposed in Table 4. The
regression lines predicting the reference value of ELA (yrs) for
the females and that for the males are given by Eq. (4) and 5
(Box 4).Box 4ELA simplified reference equations
Eq. (4) for females: ELA (yr) = 64.64  8.00 · FEV1
(L)  0.17 · BMI (kg/m2) + 8.82 · Height (m)
Eq. (5) for males: ELA (yr) = 42.85  20.74 · FEV1
(L) + 47.41 · BSA (m2)  0.62 · BMI (kg/m2)Table 2 Anthropometric and spirometric data of validation groups
Group III: COPD patients
Male Female
(n= 65) (n= 26)
Chronological-Lung-Age (Yr) 62.4 ± 9.5a 57.0 ± 15.2a
Estimated-Lung-Age (Yr) 81.1 ± 12.0a,c 65.8 ± 3.0a,c
Height (m) 1.70 ± 0.06a 1.53 ± 0.06a
Weight (kg) 71 ± 13 63 ± 18a
Body-Mass-Index (kg/m2) 24.8 ± 4.2a 26.9 ± 7.0
Body-Surface-Area (m2) 1.81 ± 0.17 1.60 ± 0.21a
Parity (numerical) Not determined
FEV1 (L) 1.57 ± 0.63
a 0.96 ± 0.33a
FEV1 (%) 52 ± 19
a 41 ± 17a
FVC (L) 2.75 ± 0.84a 1.65 ± 0.49a
FVC (%) 72 ± 18a 56 ± 19a
FEV1/FVC (absolute value) 0.56 ± 0.11
a 0.58 ± 0.08a
MMEF (L/s) 0.80 ± 0.41a 0.54 ± 0.23a
MMEF (%) 24 ± 12a 19 ± 8a
Obesity status
Normal weight 34 (52)b 11 (42)b
Overweight 26 (40) 7 (27)b
Obesity 5 (8)b 8 (31)
For abbreviations, see abbreviation list. Data are mean ± SD except for
a p< 0.05 (Student-test for groups III or IV vs. group I): male vs. mal
b p< 0.05 (Chi-2 for groups III or IV vs. group I): male vs. male, fem
c p< 0.05 (Non parametric-test): ELA vs. CLA for male, female andThe cumulative r2 was 0.38 for the female equation and 0.56
for the male equation.
The ELA in either sex followed the normal distribution
with no dependence on the ELA and its ULN and LLN were
±14.77 years in females and ±16.90 years in males (Table 4).
Fig. 1 shows the Bland and Altman [32] representation for
the group I, of CLA with ELA determined from local retained
reference equations presented in Box 4. The means ± SD of
the deltaLA of males and females are closest to zero, respec-
tively, 0.00 ± 10.22 years and 0.00 ± 8.97 years.
Validation of the retained reference equations
ELA in group II (healthy subject’s validation group): the overall
relationship between ELA (X-axis) predicted from respective
regression line and CLA (Y-axis) was Y= 10.88 + 0.79 · X
for the males (Fig. 2A) and Y= 20.26 + 1.37 · X for the fe-
males (Fig. 2B). There was no signiﬁcant difference between
CLA and ELA in either sex (Table 1, Fig. 3). The male and fe-
male means ± SD deltaLA were not signiﬁcant (respectively,
2.70 ± 12.80 years and 3.50 ± 9.00 years). The number (rel-
ative frequency) of participants in whom ELA exceeded the
ULN or LLN was two (9.5%) in females and three (15.0%)
in males (Fig. 3), indicating an acceptable agreement between
ELA and CLA in either sex.
ELA in group III (COPD validation group): the ELAs
(evaluated from the regression Eqs. (4 and 5)) of COPD males,
females and total sample patients were signiﬁcantly higher
than their CLA (Table 2) (respectively, 81.10 ± 12.00 vs.
62.40 ± 9.50 yrs; 65.80 ± 3.00 vs. 57.00 ± 15.20 yrs and
76.70 ± 12.40 vs. 60.80 ± 111.60 yrs). The relative frequency
of COPD patients in whom ELA exceeded the ULN was
26.9% in the female and 56.9% in the male. The 93 COPD
were divided into four categories for the sake of convenience,: groups III and IV.
Group IV: OSA patients
Total sample Male Female Total sample
(n= 91) (n= 42) (n= 18) (n= 60)
60.8 ± 11.6a 46.2 ± 10.4 54.5 ± 8.08 48.7 ± 10.4
76.7 ± 12.4a,c 57.8 ± 17.1a,c 55.5 ± 2.8a 57.1 ± 14.4a,c
1.65 ± 0.09 1.72 ± 0.06a 1.55 ± 0.07a 1.66 ± 0.10
69 ± 15a 102 ± 15a 96 ± 13a 101 ± 14a
25.4 ± 5.2a 34.9 ± 4.8a 40.4 ± 5.4a 36.5 ± 5.6a
1.75 ± 0.20a 2.14 ± 0.15a 1.93 ± 0.151a 2.08 ± 0.18a
4 ± 2
1.40 ± 0.62a 3.13 ± 0.83 1.97 ± 0.40a 2.78 ± 0.90a
49 ± 19a 88 ± 19a 93 ± 13a 89 ± 17a
2.44 ± 0.90a 3.86 ± 0.94 2.38 ± 0.52a 3.42 ± 1.08
68 ± 20a 89 ± 18a 94 ± 11a (90 ± 16a
0.57 ± 0.10a 0.81 ± 0.08a 0.83 ± 0.07 0.81 ± 0.07a
0.73 ± 0.39a 3.40 ± 1.36a 2.37 ± 0.64a 3.09 ± 1.27a
23 ± 11a 83 ± 30a 79 ± 20a 82 ± 27a
45 (50)b 1 (2b 0 (0)b 1 (2)b
33 (36)b 2 (5)b 0 (0)b 2 (3)b
13 (14)b 39 (93)b 18 (100)b 57 (95)b
obesity status (data are number (%)).
e, female vs. female or total sample vs. total sample).
ale vs. female or total sample vs. total sample).
the total sample.
Table 3 Inﬂuencing factors of the Estimated-Lung-Age (ELA): linear stepwise multiple regression models.
Independent variables Partial regression
coeﬃcient
95% CI p-Level Cumul ive r2 SE 1.64 · Residual Standard
Deviation
Female (n = 364)
Constant 52.83 34.37 to 71.30 0.01 11.26 14.04
FEV1 (L) 3.64 7.81 to 0.54 0.15 0.3798
Parity (numerical) 1.16 0.81 to 1.58 0.01 0.4310
PEF (L/s) 1.08 0.33 to 1.83 0.02 0.4363
MMEF (L/s) 1.54 2.80 to 0.28 0.04 0.4419
FVC (L) 3.30 6.28 to 0.32 0.07 0.4452
Height (m) 11.27 1.01 to 23.56 0.13 0.4488
Body-Mass-Index (kg/
m2)
0.15 0.37 to 0.08 0.28 0.4508
FEF25 (L/s) 0.47 1.22 to 0.29 0.31
Male (n = 176)
Constant 53.37 39.67 to 67.08 0.01 8.36 15.91
FEF25 (L/s) 4.12 7.21 to 1.04 0.03 0.4262
FVC (L) 6.26 11.25 to 1.27 0.04 0.4972
Body-Surface-Area (m2) 36.54 25.20 to 47.89 0.01 0.5677
FEV1 (L) 8.19 15.33 to 1.05 0.06 0.5809
Body-Mass-Index (kg/
m2)
0.45 0.90 to 0.01 0.11 0.5909
FEF50 (L/s) 3.66 1.95 to 5.36 0.01 0.5999
MMEF (L/s) 5.17 7.79 to 2.56 0.01
Total sample (n = 540)
Constant 210.67 104.20 to 317.14 0.01 64.92 15.70
FEV1 (L) 5.48 9.33 to 1.63 0.02 0.3504
PEF (L/s) 2.17 1.55 to 2.78 0.01 0.3883
Height (m) 265.40 407.95to 122.86 0.01 0.4125
Sex (0. Male; 1.
Female)
3.84 2.34 to 5.34 0.01 0.4308
MMEF (L/s) 2.97 4.08 to 1.86 0.01 0.4529
FVC (L) 3.98 6.72 to 1.25 0.02 0.4582
FEF25 (L/s) 0.84 1.66 to 0.03 0.09 0.4621
Body-Surface-Area (m2) 289.51 137.28 to 441.74 0.01 0.4640
Weight (kg) 2.27 3.85 to 0.69 0.02 0.4713
Body-Mass-Index (kg/
m2)
1.94 3.59 to 0.28 0.06
For abbreviations, see abbreviations list. 95% CI: 95% conﬁdence interval around each partial regression coefﬁcient. p: probability. SE: tandard error.
Proposed model for females: ELA (yr) = 52.83  3.64 · FEV1 + 1.16 · Parity + 1.08 · PEF  1.54 ·MMEF  3.30 · FVC+ 11.27 ·H ight  0.15 · Body Mass Index – 0.47 · FEF25.
Proposed model for males: ELA (yr) = 53.37  4.13 · FEF25  6.26 · FVC+ 36.54 · Body Surface Area  8.19 · FEV1  0.45 · Body ass Index + 3.66 · FEF50  5.17 ·MMEF.
Proposed model for the total sample: ELA (yr) = 210.675.48 · FEV1+ 2.17 · PEF  265.41 · Height + 3.84 · Sex  2.97 ·MMEF -3.99 · FVC  0.85 · FEF25 + 289.51 · Body Surface
Area  1.94 · Body Mass Index.
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Table 4 Simpliﬁed reference equation for the Estimated-Lung-Age (ELA).
Independent
variables
Partial regression
coeﬃcient
95% CI p-Level Cumulative r2 SE Lower-limit-of-normal
(LLN) Upper-limit-of-normal
(ULN)
Female (n = 364)
Constant 64.64 45.75 to 83.53 0.01 11.52 14.77
FEV1 (L) 8.00 9.39 to 6.61 0.01 0.3798
Body-Mass-Index (kg/m2) 0.17 0.41 to 0.06 0.22 0.3825
Height (m) 8.82 3.79 to 21.43 0.25
Male (n = 176)
Constant 42.85 29.12 to 56.58 0.01 8.37 16.90
FEV1 (L) 20.74 23.17 to 18.31 0.01 0.3957
Body-Surface-Area (m2) 47.41 36.55 to 58.28 0.01 0.5527
Body-Mass-Index (kg/m2) 0.62 1.09 to 0.14 0.03
Total sample (n = 540)
Constant 259.28 148.89 to 369.68 0.01 67.31 16.43
FEV1 (L) 11.54 12.80 to 10.28 0.01 0.3504
Height (m) 335.75 483.01 to 188.50 0.01 0.3874
Sex (0. Male; 1. Female) 2.68 1.14 to 4.22 0.01 0.3997
Body-Surface-Area (m2) 359.87 202.45 to 517.29 0.01 0.4031
Weight (kg) 2.75 4.39 to 1.10 0.01 0.4144
Body-Mass-Index (kg/m2) 2.60 4.32 to 0.88 0.01
For abbreviations, see abbreviations list. 95% CI: 95% conﬁdence interval around each partial regression coefﬁcient. p: Probability. SE:
standard error. Proposed models: Female: ELA (yrs) = 64.64106  8.00049 · FEV1  0.17411 · Body Mass Index + 8.82107 ·Height. To
calculate LLN or ULN subtract or add 14.77 yrs to the ELA. Male: ELA (yrs) = 42.8499  20.7404 · FEV1+47.4141 · Body Surface
Area  0.6164 · Body Mass Index. To calculate LLN or ULN subtract or add 16.90 yrs to the ELA.
498 H. Ben Saad et al.i.e., grade I (9 males/1 female), grade II (31 males/9 females);
grade III (21 males/12 females) and grade IV (4 males/4
females). The deltaLA averaged 1.84 years in the COPD
patients with grade I, +13.34 years in those with grade II,
+21.68 years in those with grade III, or +26.42 years in those
with grade IV (Fig. 4). The deltaLA in COPD patients with
grades III and IV, but not in those with grades I and II, cer-
tainly exceeded the ULN, indicating that allowance was made
for judging that only the ELA in subjects with COPD grades-
III or IV was signiﬁcantly older than the CLA.
ELA in group IV (severe OSA validation group): the ELAs
(evaluated from the regression Eqs. (4 and 5)) of severe OSA
males and total sample patients were signiﬁcantly higher than
their CLA (Table 2). The relative frequency of severe OSA pa-
tients in whom ELA exceeded the ULN was 5.5% in females
and 30.9% in males.
Effect of parity: in the entire female population (n= 364), a
positive univariate linear correlation was found between CLA
and parity (Table A.1, Appendix A) (r= 0.51, p< 0.05). Par-
ity also appeared to be a positive independent variable in-
cluded in the forward linear stepwise multiple regression
model for ELA (Table 3). No correlation between parity and
BMI (p= 0.90) was found. But there exist signiﬁcant
(p< 0.05) correlations between parity and weight, height
and FEV1 (r= 0.43, r= 0.28, r= 0.16, respectively).
ELA from the Japanese reference equations: the ELA in par-
ticipants of group II was calculated according to Yamaguchi
et al. [6] reference equations. The overall relation between
ELA [6] (X-axis) and CLA (Y-axis) was expressed as
Y= 7.54 + 0.68 · X in males and Y= 1.42 + 0.56 · X in fe-
males (Fig. 5). The determination coefﬁcients (=0.20 (Fig. 5A)
and 0.32 (Fig. 5B), respectively for males and females) werelower than those determined from retained local reference
equations (=0.43 (Fig. 2A) and 0.60 (Fig. 2B), respectively
for males and females). The ﬁtted lines revealed a discrepancy
between CLA and ELA (Fig. 5). This suggests that the Japa-
nese reference equations [6] inevitably overestimated the
CLA in males (Fig. 5A) (mean ± SD difference = 9.40 ±
15.20 yrs, p< 0.05) and underestimated the CLA in females
(Fig. 5B) (mean ± SD difference = 1.50 ± 12.70 yrs,
p= 0.72). The relative frequency of participants in whom
ELA determined from Japanese reference equations [6] ex-
ceeded the ULN or LLN was 29.2%.
Algorithm for judging the abnormality from ELA: when
judging the abnormality in ELA three-step procedures are rec-
ommended (Fig. 6). The ﬁrst thing to do is to examine whether
the deltaLA exists within normal limits formed by ULN and
LLN, i.e., ±16.90 years in the male and ±14.77 years in the
female. If deltaLA:
(i) Exists within ULN and LLN, the ELA of a person
should be interpreted to be consistent with his/her
CLA, even when the ELA is above or below the CLA.
(ii) Exceeds ULN, the ELA is judged to be older than the
CLA.
(iii) Is below LLN, the ELA is judged to be younger than the
CLA.
Discussion
Novel regression equations allowing prediction of reference
value of ELA and normal limits of difference between ELA
and CLA were elaborated in both sexes for North African
Figure 1 Group I (equation group: healthy never-smokers with
normal spirometric measurements): Bland and Altman represen-
tation of Chronological-Lung-Age (CLA) with Estimated-Lung-
Age (ELA) determined from retained local reference equations.
(A) Male. (B) Female. r2: determination coefﬁcient; r: correlation
coefﬁcient; p: probability; n= number of subjects. : Mean;
: mean ± 1.96 ± SD; : regression line.
igure 2 Group II (validation group: healthy never-smokers with
ormal spirometric measurements): comparison of Estimated-
ung-Age (ELA) determined from the retained local reference
quations with Chronological-Lung-Age (CLA). (A) Male. (B)
emale. r2: determination coefﬁcient; r: correlation coefﬁcient; p:
robability; n= number of subjects. : regression line. :
entity line.
Lung age of North African adults 499adult population. In additional groups of healthy or adult-pa-
tients prospectively assessed, the present reference equations
yielded satisfactory predictions.
Methodology discussion
The study design, the population source, the sample size and
characteristics of group I subjects, the applied inclusion and
non-inclusion criteria, the spirometry measurements were pre-
viously discussed [9]. In addition, the ELA published reference
equation was extensively described in a previous paper [9].
The statistical analysis was similar to that previously very
well described by Yamaguchi et al. [10]. The regression equa-
tion predicting the normal value of a given pulmonary func-
tional parameter for non-smoking healthy adults is generally
constructed by taking spirometric parameter as dependent var-
iable, while sex, age and height as independent variables, in
terms of least-square minimization. In the original method of
Morris and Temple [3], calculation of ELA (X) was made by
counting back the regression equation predicting the normal
value of a given spirometric parameter expressed by
Y= a+ b · X in a ﬁxed condition of sex and height, i.e.,
X= a/b+ Y/b. According to Yamaguchi et al. [10], thisF
n
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idmay not be approvable in a statistical sense and, for estimating
LA with statistical validity, it is necessary to establish the new
regression equation by taking age as dependent variable but
spirometric parameter as independent variable using the same
data set. In addition, normal value of a spirometric parameter
at a given age exists within a certain range between ULN and
LLN, corresponding to maximum and minimum ends of 95%
CI, which are deﬁned as mean ± 2ÆRSD [10].
Study limitations
As for the Japanese study [6], one of the crucial issues
acknowledged is that we have no reliable grounds for support-
ing the idea that the relationship between lung aging and var-
ious spirometric parameters can be approximated by the linear
function. However, it was demonstrated that, in the male, peak
of FEV1 or FVC would be attained at an age between 20 and
25 years-old and then declined with age, but, in the female, full
lung growth would be achieved earlier than the male [33].
These ﬁndings suggest that the relation between CLA and
most of the spirometric parameters is approximated by a linear
function as far as the subjects studied are over 20 years-old and
their spirometry is normal [10]. However, it may be difﬁcult to
Figure 3 Group II (validation group: healthy never-smokers with
normal spirometric measurements): Bland and Altman represen-
tation of Chronological-Lung-Age (CLA) with Estimated-Lung-
Age (ELA) determined from retained local reference equations.
(A) Male. (B) Female. r2: Determination coefﬁcient; r: correlation
coefﬁcient; p: probability; n= number of subjects. : Mean;
: mean ± 1.96 ± SD; : regression line.
Figure 4 Group III (patients’ validation group: Chronic Obstruc-
tive Pulmonary Disease (COPD)): difference between Estimated-
Lung-Age (ELA) and Chronological-Lung-Age (CLA) (delta LA).
Values are means and their 95% conﬁdence intervals. Severity of
airﬂow obstruction in COPD: grade I (n= 10): 1.84 yrs (8.35
to 4.66), grade II (n= 40):+13.34 yrs (9.81 to 16.88), grade III
(n= 33):+21.68 yrs (16.17 to 27.19) and grade IV
(n= 8):+26.42 yrs (18.96 to 33.88). : mean. : 95% CI.
Dotted line: average of male ULN and female ULN for delta LA
(+15.84 yrs). The difference between the 4 COPD grades was
judged in terms of the one-way ANOVA followed by the multiple
comparison of the Turkey test. a: Larger than grade I (p< 0.05).
b: Larger than grade II (p< 0.05). c: Larger than grade III
(p< 0.05).
500 H. Ben Saad et al.say that these ﬁndings sufﬁciently provide the physiologically
relevant grounds for the linear assumption between ELA and
various spirometric parameters [10]. Therefore, as in another
study [6], their applicability was validated by calculating the
ELAs of subjects with normal spirometry and those with dete-
riorating pulmonary function.
Results and discussion
How to evaluate ‘‘spirometric’’ ELA for North African
population? What method is approvable?
The spirometric ELA is offered as a tool to impress upon the
smoker the degree of ventilatory defect caused by tobacco
smoke inhalation. As part of an educational program used
by a physician or health professional, it can provide additional
incentive to prevent further loss of pulmonary function and the
potential for improved function and LA reduction [3].
Morris and Temple [3] deserve credit for introducing the
concept of ELA to assess airﬂow obstruction. Parkes et al.
[34] found their ELAs useful, but they are not routinely calcu-
lated. Using the new formulas (Eqs. (4) and (5)) presented in
the present study, anyone can easily manually calculate and
inform patients of their ELAs from any spirometric report.
This should elicit a response and open discussion regardingthe dangers of continuing smoking. Referral to support
groups, educational and counseling sessions, and the use of
newer pharmaceuticals all offer avenues for success [34,35].
The recommended sequence (Fig. 6) is to identify a smoker,
perform spirometry, and, if the FEV1, is less than the LLN,
estimate the LA.
The variability of spirometry results of normal healthy sub-
jects is itself quite wide, being approximately 80–120% pre-
dicted, and consequently wide variation in ELA exists. There
continues to be a considerable debate about the use of LLN
or percent predicted, with the deﬁnitions of stages of disease
easily described by percent predicted [6]. Instead of a single
ELA value it may be possible to communicate ELA as being
‘‘LLN and ULN’’, based on 95% CI [6,10]. LA’s relationship
to smoking may also be controversial as there is also a decline
in lung function with increasing age as well as with diseases
such as COPD. However, there is continued support in the lit-
erature for the more rapid decline in FEV1 in smokers than in
non-smokers [36,37].
It should be noted that the Eqs. (4) and (5) are only appli-
cable to the North African population. However, we anticipate
that the ﬁndings obtained in the present study will promote the
development of ethnic-speciﬁc regression equations allowing
prediction of ELA in various races.
Effect of parity
Parity was positively correlated with CLA of the group I fe-
male and appeared as a positive independent variable included
in the multiple regression model for ELA. This result may be
Figure 5 Group II (validation group: healthy never-smokers with
normal spirometric measurements): comparison of Estimated-
Lung-Age (ELA) determined from Japanese reference equations
with Chronological-Lung-Age (CLA). r2: determination coefﬁ-
cient; r: correlation coefﬁcient; p: probability; n= number of
subjects. : regression line. : identity line.
Figure 6 Three-step procedure for judging the abnormality of
Estimated-Lung-Age (ELA) in North African population. For
abbreviations, see abbreviations list.
Lung age of North African adults 501clinically relevant when interpreting ELA in females from
North Africa. A simple way to solve this problem would be
to subtract, from their ELA reference value some years equal
to the number of parity multiplied by 1.16. This phenomenon
may reﬂect the general ﬁndings about aging and parity effects
on health [38] and several hypotheses, discussed in some previ-
ous paper [11–13,39], have been advanced (detailed discussion
appears in the Appendix A). Medical studies provide very little
information on the inﬂuence of parity on LA, however, this
may be a promising new direction for physiological and path-
ophysiological research, particularly for developing countries.
Validity of the North African ELA reference equations
The newly developed equations could predict not only the
equality between ELA and CLA in group II (Table 1) within
an allowable margin of error but also the incremental disparity
between ELA and CLA in groups III and IV with COPD or se-
vere OAS (Table 2). Thus, we concluded that the Eqs. (4) and (5)
would be practically useful in a clinical setting in North African
population. Similar to the ﬁndings of the Japanese study [6], in
the COPD group, the North African ELA equations produced
an ELA greater than CLA suggesting that smoking causes lungs
to deteriorate more quickly than the expected age-related de-
cline, as predicted by Fletcher and Peto [40].In conclusion, reliable reference equations to interpret the
ELA in healthy North African adults were established. The
ELA can be easily predicted from sex and easily measured/cal-
culated anthropometric data (height, BMI, BSA) in addition
to a reproducible spirometric parameter (FEV1). In additional
groups of healthy or adult-patients prospectively assessed, the
present novel reference equations yielded satisfactory predic-
tions. These reference equations enrich the World Bank of ref-
erence equations (see the Excel ‘‘Software ‘‘Lung Age’’ in
Appendix B), from which the physician should choose accord-
ing to the patient’s locale and ethnic background.
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